Akamis Bio Raises $60 Million for Groundbreaking Cancer Therapy
Akamis Bio, a pioneer in clinical-stage oncology treatments, recently made headlines by securing $60 million in funding associated with its latest financing round. This funding will further the company’s mission to leverage its proprietary Tumor-Specific Immuno-Gene (T-SIGn®) therapy platform, aimed at delivering innovative immunotherapeutic proteins to combat solid tumors.
Momentum for NG-350A Development
The financing marks a significant step forward for Akamis Bio, directly supporting the advancement of NG-350A, its lead clinical candidate. This therapy is designed to target advanced rectal cancer through a Phase 1b proof-of-concept study. NG-350A utilizes an intravenous delivery method to administer a transgene-armed tumor gene therapy, which is expected to promote targeted expression of a CD40 agonist monoclonal antibody within the tumor. This technique is designed specifically for both primary tumors and metastatic epithelial-derived solid tumors.
Focus on Clinical Proof of Concept
The FORTRESS study, the Phase 1b clinical trial associated with NG-350A, aims to evaluate the complete response rates among adult patients diagnosed with locally advanced rectal cancer. Many of these patients have at least one additional risk factor that may elevate their chances of local or distant recurrence. The results from this study are highly anticipated as they could establish a new benchmark in the treatment approach for this challenging condition.
A Partnership to Expand Market Reach
In conjunction with the financing, Akamis Bio has formed a strategic partnership with Xuanzhu Biopharma, securing the rights for NG-350A within the Greater China Region. This partnership allows Akamis Bio to receive undisclosed upfront payments, regulatory and sales milestones, along with tiered royalties based on sales of NG-350A in this lucrative market region.
Endorsement from Industry Leaders
The financing round, led by Sedgwick Yard, signals a strong confidence in Akamis Bio’s innovative therapies and management. Howard Davis, the CEO of Akamis Bio, expressed gratitude towards their partners and reiterated the company's commitment to advancing NG-350A swiftly while showcasing the broader applications of the T-SIGn technology platform. He emphasized the compelling clinical data from past studies, which demonstrated a consistent safety profile for this groundbreaking treatment.
Clinical Evidence and Future Prospects
Research published in the Journal for ImmunoTherapy of Cancer (JITC) strengthens the scientific foundation of NG-350A, showcasing its effectiveness in initial human trials aimed at metastatic epithelial tumors. This data provides promising evidence of the therapy's tumor-selective delivery and favorable pharmacokinetic profile compared to traditional therapy routes, revealing it as a potentially more viable option.
Collaboration for Patient Care
Jiakui Li, CEO of Xuanzhu Biopharma, expressed enthusiasm about collaborating with Akamis Bio to commercialize this innovative therapy in Greater China. With the T-SIGn platform poised to change the landscape for advanced cancer treatments, both companies are dedicated to expediting the therapeutic process for patients in need.
Leadership Changes Enhance Governance
The recent financing also led to the expansion of Akamis Bio’s Board of Directors, with Richard Shen and Adrian Chan joining to bring their expertise from Sedgwick Yard. Their experience in navigating the biotech landscape is expected to strengthen Akamis Bio’s ability to achieve its strategic goals.
Understanding T-SIGn Technology
At the heart of Akamis Bio's innovations is the T-SIGn® technology, which harnesses the power of a specially adapted adenovirus to deliver gene therapies directly to tumors. This approach ensures that cancerous cells receive treatment while preserving healthy tissues, which may enhance overall patient outcomes. The technology has the potential to reshape the way immuno-oncology therapies are delivered, leading to more effective and targeted cancer treatment options.
About Akamis Bio
Akamis Bio is committed to revolutionizing cancer treatment through its T-SIGn® platform, focusing on harnessing the immune system to recognize and eliminate cancer. The company is actively developing a portfolio of T-SIGn therapeutics, with a leading program, NG-350A, undergoing clinical trials aimed at addressing the critical need for more effective interventions against solid tumors. Ongoing partnerships with industry leaders reflect Akamis Bio's determination to push boundaries in the field of oncology.
Frequently Asked Questions
What is the purpose of the recent funding announcement by Akamis Bio?
The funding will support the advancement of NG-350A, its lead clinical candidate targeting advanced rectal cancer.
What are the expected outcomes of the Phase 1b study?
The study aims to evaluate clinical complete response rates of NG-350A in combination with chemoradiotherapy.
Who are Akamis Bio's partners in this endeavor?
Akamis Bio is working alongside Sedgwick Yard and Xuanzhu Biopharma to expand its market reach and development capabilities.
What makes the T-SIGn platform unique?
The T-SIGn platform targets solid tumors while sparing healthy tissues, enhancing treatment efficacy and safety.
How does NG-350A differ from traditional treatments?
NG-350A employs a novel intravenous delivery method that offers a targeted approach to gene therapy for tumors.
